Take A First Step
If current trendlines are any indication, cell therapy – and allogeneic cell therapy, more specifically – will be dominating discussions about industry innovation for years to come. More immediately, there’s another discussion that we think could prove equally interesting: One between your team and ours about how our approach to delivering on the promise of iPSCs can yield value for your science. Let’s get started here.